
On Friday morning, windswept biotech firm Orphazyme has announced its intention to resubmit an application to the US Food and Drug Administration (FDA) for arimoclomol, a potential treatment of the metabolic disease known as Niemann-Pick type C (NPC).
Orphazyme’s lead candidate was rejected by the FDA in a so-called ”complete response letter” in June of last year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app